Rohit Bishnoi
- Oncology top 10%
- Viral-associated cancers and disorders 9
- Polyomavirus and related diseases 7
- Peptidase Inhibition and Analysis 7
- Cancer Treatment and Pharmacology 3
- Hematology top 10%
- Multiple Myeloma Research and Treatments 5
-
- Diabetes Treatment and Management 7
-
- Neuroendocrine Tumor Research Advances 6
-
- Transplantation: Methods and Outcomes 3
- Co-authors
- Chintan ShahWilliam Paul SkeltonNam H. DangYu WangLong H. DangYoung‐Rock HongJan S. MorebAnkur Jain
- Journals
- Journal of Clinical Oncology (10 papers)Cancer Medicine (2 papers)Hematological Oncology (2 papers)
- Partner nations
- United StatesIndia
In The Last Decade
Rohit Bishnoi
40 papers receiving 528 citations
Peers
Comparison fields: 5 of 78
- Oncology 281
- Hematology 89
- Endocrinology, Diabetes and Metabolism 69
- Pathology and Forensic Medicine 72
- Cardiology and Cardiovascular Medicine 86
Countries citing papers authored by Rohit Bishnoi
This map shows the geographic impact of Rohit Bishnoi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohit Bishnoi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohit Bishnoi more than expected).
Fields of papers citing papers by Rohit Bishnoi
This network shows the impact of papers produced by Rohit Bishnoi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohit Bishnoi. The network helps show where Rohit Bishnoi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rohit Bishnoi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 8 | |
| 2 | 2020 | 6 | |
| 3 | 2020 | 15 | |
| 4 | 2020 | 2 | |
| 5 | 2020 | 34 | |
| 6 | 2020 | 20 | |
| 7 | 2020 | 7 | |
| 8 | 2019 | 16 | |
| 9 | 2019 | 19 | |
| 10 | 2018 | 30 | |
| 11 | 2018 | 3 | |
| 12 | 2018 | 68 | |
| 13 | 2018 | 9 | |
| 14 | 2018 | 24 | |
| 15 | 2017 | 3 | |
| 16 | 2017 | 31 | |
| 17 | 2017 | 27 | |
| 18 | 2017 | 40 | |
| 19 | 2016 | 9 | |
| 20 | 2015 | 8 |
About Rohit Bishnoi
Rohit Bishnoi is a scholar working on Oncology, Otorhinolaryngology and Hematology, having authored 40 papers that have together received 531 indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (9 papers), Polyomavirus and related diseases (7 papers), Peptidase Inhibition and Analysis (7 papers), Diabetes Treatment and Management (7 papers), Neuroendocrine Tumor Research Advances (6 papers), Multiple Myeloma Research and Treatments (5 papers), Transplantation: Methods and Outcomes (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (281 citations), Hematology (89 citations) and Endocrinology, Diabetes and Metabolism (69 citations). Rohit Bishnoi has collaborated with scholars based in United States and India. Frequent co-authors include Chintan Shah, William Paul Skelton, Nam H. Dang, Yu Wang, Long H. Dang, Young‐Rock Hong, Jan S. Moreb, Ankur Jain, Jinhai Huo and Lazarus K. Mramba. Their work appears in journals such as Journal of Clinical Oncology, Cancer Medicine, Hematological Oncology, Cancer Prevention Research and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.